Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
Carlyn Tan, Sireesha Asoori, Chiung‐Yu Huang, Larissa Brunaldi, Rakesh Popat, Efstathios Kastritis, Joaquín Martínez‐López, Radhika Bansal, Andre De Menezes Silva Corraes, Saurabh Chhabra, Ricardo Parrondo, Sikander Ailawadhi, Despina Fotiou, Meletios A Dimopoulos, Kwee Yong, Catriona Mactier, Chris Lau, Magdalena Corona, Adolfo Sáez, Hira Mian, Brian G.M. Durie, Saad Z. Usmani, Thomas G. Martin, Yi Lin (2025). Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study. , 15(1), DOI: https://doi.org/10.1038/s41408-025-01259-z.
Article37 days agoEarly Mortality Associated with Real-World Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma
Carlyn Tan, Sireesha Asoori, Andriy Derkach, Rakesh Popat, Efstathios Kastritis, Joaquín Martínez‐López, Radhika Bansal, Andre De Menezes Silva Corraes, Saurabh Chhabra, Ricardo Parrondo, Sikander Ailawadhi, Despina Fotiou, Meletios A Dimopoulos, Kwee Yong, Catriona Mactier, Chris Lau, Magdalena Corona, Adolfo Sáez, Brian G.M. Durie, Saad Z. Usmani, Yi Lin, T. John Martin, Hira Mian (2025). Early Mortality Associated with Real-World Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)03559-1.
Article37 days agoComparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites
Shaji Kumar, Sundar Jagannath, Katja Weisel, Laura Rosiñol Dachs, Meletios A Dimopoulos, David S. Siegel, Jorge Monge, Xavier Leleu, Juan Du, Javier de la Rubia, Jae Hoon Lee, María-Victoria Mateos, Alessandro Gozzetti, Dominik Dytfeld, Enrique M. Ocio, Joan Bladé, Shuji Ozaki, Madhu Nagaraj, Rafla Hassan, Jeannette Green, Glenn S. Kroog, Karen Rodriguez Lorenc, Christian Hampp, Qiufei Ma, Brian G.M. Durie (2024). Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-210376.
Article37 days agoLong-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee
Carlyn Tan, Sireesha Asoori, David Nemirovsky, Andriy Derkach, Larissa Brunaldi, Rakesh Popat, Chris Lau, Efstathios Kastritis, Joaquín Martínez‐López, Radhika Bansal, Andre De Menezes Silva Corraes, Saurabh Chhabra, Ricardo Parrondo, Sikander Ailawadhi, Despina Fotiou, Meletios A Dimopoulos, Kwee Yong, Catriona Mactier, Magdalena Corona, Adolfo Jesús Sáez Marín, Hira Mian, Saad Z. Usmani, Brian G.M. Durie, Thomas G. Martin, Yi Lin (2024). Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-210518.
Article37 days agoComparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis
Shaji Kumar, Sundar Jagannath, Katja Weisel, Laura Rosiñol Dachs, Meletios A Dimopoulos, David S. Siegel, Jorge Monge, Xavier Leleu, Juan Du, Javier de la Rubia, Jae Hoon Lee, María‐Victoria Mateos, Borja Puertas Martínez, Alessandro Gozzetti, Dominik Dytfeld, Enrique M. Ocio, Joan Bladé, Shuji Ozaki, Meral Beksaç, Fernando Escalante, Madhu Nagaraj, Rafla Hassan, Paul Spin, Nicolle Bonar, Mostafa Shokoohi, Muhaimen Siddiqui, Di Wang, Kevin Hou, Jeannette Green, Olivier Humblet, Alexander Breskin, James Harnett, Wenzhen Ge, Rachel E. Sobel, Jessica J. Jalbert, Glenn S. Kroog, Karen Rodriguez Lorenc, Qiufei Ma, Christian Hampp, Brian G.M. Durie (2024). Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-200679.
Article37 days ago